Current Medical Research and Opinion最新文献

{"title":"GPP 2022: perspectives, sentiments, and feedback from the publications community.","authors":"Raghuraj Puthige, Dikran Toroser, Anisha Mehra, Dhanya Mukundan, Anupama Kapadia","doi":"10.1080/03007995.2025.2503975","DOIUrl":"10.1080/03007995.2025.2503975","url":null,"abstract":"<p><strong>Objective: </strong>To identify the impact and integration of GPP 2022 guidelines on the work processes of publications developed in pharmaceutical, publishing, agency, and academic circles.</p><p><strong>Methods: </strong>A cross-sectional survey was conducted for 3 weeks from March 1-22, 2024 among medical publication professionals and healthcare researchers. The survey included questions that have been traditionally challenging in publication workstreams and were disseminated through major medical communications networking groups. The survey results were summarized as a percentage for each answer rounded to one decimal place.</p><p><strong>Results: </strong>A total of 100 participants responded to the survey among whom 67.0% were familiar with the GPP 2022 guidelines. To mitigate potential misinterpretation risks, we considered only respondents familiar with the guidelines. More than half of the respondents (55.7%) felt that GPP 2022 was effective in addressing ethical considerations; 34.4% respondents agreed that GPP 2022 provided useful guidance on best practices in transparency and data-sharing. Most survey respondents (54.5%) agreed that the authorship and contributorship criteria were clear in GPP 2022. 37.3% of the survey respondents were familiar with publication extenders and felt that extenders added value to the dissemination of research findings; 39.2% were aware of plain-language summaries and 82.4% viewed them as vital for widespread research accessibility.</p><p><strong>Conclusion: </strong>The survey suggests a need to improve awareness and support for implementing transparency initiatives that aid in the publication process. Furthermore, although most respondents were aware of publication extenders, there was a need for clarification and harmonization of guidelines on publication extenders.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"879-885"},"PeriodicalIF":2.4,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143995305","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessment of appetite loss and related factors in older patients with cancer: validation of the cancer appetite and symptom questionnaire (CASQ) in Turkish patients.","authors":"Digdem Dogan Akagunduz, Hilal Şahin, Ferhan Elmalı, Baran Akagunduz","doi":"10.1080/03007995.2025.2502669","DOIUrl":"10.1080/03007995.2025.2502669","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to validate the Cancer Appetite and Symptom Questionnaire (CASQ) for Turkish older cancer patients and identify factors influencing appetite loss and related symptoms. The research question focused on whether the CASQ is a reliable tool for assessing appetite-related symptoms and determining associated risk factors in this population.</p><p><strong>Methods: </strong>A total of 240 cancer patients aged ≥70 years were recruited from a Turkish oncology clinic. Demographic, cancer-related, nutritional, functional, and psychological data were collected. Appetite was assessed using the CASQ and Simplified Nutritional Appetite Questionnaire (SNAQ). Structural validity, reliability, and diagnostic performance were evaluated through exploratory factor analysis (EFA) and confirmatory factor analysis (CFA). Logistic regression was performed to identify factors associated with appetite loss.</p><p><strong>Results: </strong>The CASQ demonstrated high reliability and validity, with a Cronbach's alpha of 0.971 and Kaiser-Meyer-Olkin (KMO) of 0.907. EFA and CFA supported a single-factor structure. A CASQ cutoff score of 32 showed high diagnostic accuracy (AUC: 0.971) with 88.9% sensitivity. Appetite loss was reported in 53.7% of patients and was significantly associated with stage IV cancer (OR: 10.112, <i>p</i> < .001), chemotherapy (OR: 2.960, <i>p</i> = .016), severe pain (OR: 3.089, <i>p</i> = .003), malnutrition (OR: 4.459, <i>p</i> = .033), polypharmacy (OR: 2.213, <i>p</i> = .040), and poor performance status (OR: 5.245, <i>p</i> = .017).</p><p><strong>Conclusions: </strong>The CASQ is a validated, reliable tool for assessing appetite-related symptoms in Turkish older cancer patients. Findings underscore the need for integrated nutritional and psychological care. Future research should develop targeted interventions to mitigate appetite loss and its impact on quality of life in this population.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"789-797"},"PeriodicalIF":2.4,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144076521","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Functional improvement as a treatment goal in major depressive disorder: a narrative review of the evidence for vortioxetine.","authors":"Pratap Chokka, Lene Hammer-Helmich, Simon Nitschky Schmidt, Martine Hubert, Elin H Reines, Iria Grande","doi":"10.1080/03007995.2025.2503976","DOIUrl":"10.1080/03007995.2025.2503976","url":null,"abstract":"<p><p>This narrative review used manufacturer-sponsored vortioxetine clinical trial database (doses of 5-20 mg) to evaluate the effect of vortioxetine treatment on short- and long- term functional outcomes in major depressive disorder (MDD), in both the clinical trial setting and in routine practice. The Sheehan Disability Scale (SDS) was the most used functional scale and, based on this measure, short-term, placebo-controlled studies demonstrated significant improvements with vortioxetine 10 mg (reductions ranged from -0.92 to -2.10 points vs placebo after 6-8 weeks treatment) and 20 mg (reductions ranged from -0.88 to -3.92 vs placebo). Of note, the acute beneficial effects of vortioxetine on functionality were seen in patients with severe baseline depressive symptoms as well as those with significant anxiety. Long-term open-label extension studies further showed that maintenance treatment was associated with continued functional improvements over one year (reaching an average reduction of -6.2 SDS points from baseline) that were correlated with continued improvements in residual symptoms. Evidence from real-world studies, using multiple functional outcomes, further demonstrated generalizability to routine practice where patients are living with multiple comorbidities previously excluded from the randomized controlled trials. Taken overall, the findings from several head-to-head studies indicated a functional advantage of vortioxetine compared with other classes of antidepressants and demonstrated the effectiveness of vortioxetine as first-line treatment while also confirming its effectiveness in improving functional outcomes when given later in the treatment journey. In summary, vortioxetine is an effective treatment option for improving functional outcomes in people living with MDD.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"855-866"},"PeriodicalIF":2.4,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144076530","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient-reported real-world experience of risankizumab on-body device (OBD) for the treatment of Crohn's disease in the UK (COMMODUS).","authors":"Adil Jaulim, Anna Stanton, Sherill Tripoli, Ana Ibarra, David Young, Mary Doona, Fraser Cummings, Ally Speight, Shahida Din, James O Lindsay, Rachel Horsfall, Mark Sephton, Mark A Samaan","doi":"10.1080/03007995.2025.2506808","DOIUrl":"10.1080/03007995.2025.2506808","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate real-world patient-reported experience with subcutaneous (SC) risankizumab administered by on-body device (OBD) in patients with Crohn's disease (CD).</p><p><strong>Methods: </strong>Uncontrolled observational cross-sectional study in five UK units between October 2023 and May 2024. Patients who had received maintenance risankizumab <i>via</i> SC injection of four pre-filled syringes (PFS) self-administered in hospital were switched to OBD self-injection. Self-Injection Assessment Questionnaires (SIAQ) were completed pre- and post-first OBD use. The primary end-point was \"Overall, how satisfied are you with your current way of taking your medication (self-injection)?\" from post-injection SIAQ. Baseline patient data were collected retrospectively from medical records.</p><p><strong>Results: </strong>The study recruited 50 patients with moderate-to-severe CD, 48 completed the study. Most (81%) were satisfied/very satisfied with self-injection using OBD vs only 54% with PFS. Satisfaction with the OBD was highest with home use (90% vs 65%). Confidence was high with the OBD; numerically higher rates of patients were confident in giving themselves an injection in the right way (83% vs 64%), in a clean and sterile way (90% vs 74%) and safely (85% vs 72%) post-OBD than before using OBD. Self-injection using the OBD was reported as easy by 92% and convenient by 83% of participants. Most participants reported that they would continue to use the OBD (82%) and be confident to self-inject at home (81%). The OBD was well tolerated.</p><p><strong>Conclusion: </strong>The OBD provides a safe, easy to use and convenient way to self-administer risankizumab at home using one injection with improved satisfaction and confidence vs self-administration of four PFS in hospital.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"829-839"},"PeriodicalIF":2.4,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144119151","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Improving CRC screening in an underserved population: real-world adherence to mt-sDNA testing among the incarcerated in Nebraska, United States.","authors":"Mallik Greene, Timo Pew, A Burak Ozbay, Durado Brooks, Jerry L Lovelace","doi":"10.1080/03007995.2025.2517696","DOIUrl":"10.1080/03007995.2025.2517696","url":null,"abstract":"<p><strong>Objectives: </strong>This study assessed adherence to colorectal cancer (CRC) screening with a multi-target stool DNA (mt-sDNA) test in a real-world, carceral setting.</p><p><strong>Methods: </strong>This was a retrospective observational study in a prison system using laboratory data from Exact Sciences Laboratories LLC. Individuals aged 45-85 years incarcerated by the Nebraska Department of Correctional Services (Nebraska, United States) covered under a single National Provider Identifier were included. Participants underwent CRC screening evaluation at the prison's medical center (June 1, 2023-April 1, 2024). Adherence and the time to test return (days) were evaluated overall and across patient characteristics.</p><p><strong>Results: </strong>A total of 189 patients were included (50-64 years: 78.3%; male: 94.7%). Overall adherence was 92.6%. Adherence was numerically higher in those aged 65-75 years and in participants from rural and small-town correctional facilities (95.2% each). Mean overall time to test return from shipment of mt-sDNA kit to receipt of a valid test was 21 days, with numerically shortest time to test return in participants aged 45-49 years (18.8 days), from small-town correctional facilities (19.2 days), and females (17.3 days). Overall mt-sDNA test positivity rate was 17.7%.</p><p><strong>Conclusion: </strong>High rates of adherence to the mt-sDNA test were observed in an underserved, incarcerated population, suggesting the potential of this screening approach in increasing rates of CRC screening and completion in this population. Future investigation into the possible individual-, provider-, and system-level benefits that may be obtained through broader adoption of the mt-sDNA screening test is warranted.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"809-816"},"PeriodicalIF":2.4,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144246804","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Equivalent healthcare resource use following either a long-acting steroid-eluting implant or repeat endoscopic surgery for chronic rhinosinusitis patients with nasal polyp recurrence: a real-world evidence study.","authors":"Becca S Feldman, Jason Nelson, Xiaomin Deng, Karen McKenzie, James E Kallman","doi":"10.1080/03007995.2025.2513955","DOIUrl":"10.1080/03007995.2025.2513955","url":null,"abstract":"<p><strong>Objective: </strong>To compare the impact of a long-acting steroid-eluting sinus implant (Implant) against repeat endoscopic sinus surgery (ESS) for nasal polyp recurrence after initial ESS on healthcare resource use (HCRU) in patients with chronic rhinosinusitis with nasal polyps (CRSwNP).</p><p><strong>Methods: </strong>This retrospective, observational cohort study using linked claims and electronic medical records (EMR) real-world data included CRSwNP patients who received the Implant for recurrent NP. Patients receiving the Implant were matched to patients undergoing repeat ESS using a propensity score <i>via</i> baseline characteristics. Patients in both cohorts were required to have at least 12 months' data before the index procedure. Subsequent HCRU over 18 months was compared between the cohorts using chi-square tests.</p><p><strong>Results: </strong>The final study population consisted of 267 patients receiving the Implant (mean age 49.6 ± 15.2 years, 55.1% male) matched to 267 patients undergoing repeat ESS. During the follow-up period, both cohorts saw statistically equivalent HCRU across multiple types of all-cause patient encounters: outpatient (98.1% versus 98.9%, <i>p</i> = 0.476), otolaryngology (82.0% versus 75.3%, <i>p</i> = 0.057) and emergency room (18.4% versus 21.0%, <i>p</i> = 0.446). For the Implant cohort nasal endoscopy procedures were higher (78.7% versus 68.2%, <i>p</i> < 0.006) and sinus debridement procedures were lower (51.7% versus 72.3%, <i>p</i> < 0.001). Both cohorts saw statistically equivalent efficacy in avoiding subsequent interventions in either biologics or repeat ESS (27.0% versus 26.2%, <i>p</i> = 0.845). Cost estimates yielded a lower cost ($3,735 or 18.4% less) for Implant ($16,531) than for repeat ESS ($20,265).</p><p><strong>Conclusion: </strong>Observed HCRU for CRSwNP patients after receiving the Implant was no different than after repeat ESS. Efficacy in avoiding subsequent interventions was likewise equivalent. Cost estimates suggest the Implant is lower cost than repeat ESS. Given similar impacts on HCRU/clinical efficacy and potential lower cost, the Implant may warrant consideration over repeat ESS as first-line intervention for CRSwNP patients with NP recurrence.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"767-777"},"PeriodicalIF":2.4,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144233459","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessing the symptom control provided by ravulizumab or efgartigimod in myasthenia gravis: an evaluation of the patient experience of two different treatment approaches.","authors":"Christopher A Scheiner, Masayuki Masuda, Tim Hagenacker, Lauren Powell, Pramoda Jayasinghe, Karissa Johnston, Karen S Yee","doi":"10.1080/03007995.2025.2497906","DOIUrl":"10.1080/03007995.2025.2497906","url":null,"abstract":"<p><strong>Objective: </strong>To introduce patient-centric perspectives of symptom control using a novel modeling approach to estimate time spent in health states for the generalized myasthenia gravis (gMG) therapies ravulizumab (terminal complement inhibitor) and efgartigimod (neonatal Fc receptor antagonist).</p><p><strong>Methods: </strong>Myasthenia Gravis Activities of Daily Living (MG-ADL), Quantitative Myasthenia Gravis (QMG), and Myasthenia Gravis Quality of Life 15-item revised (MG-QOL15r) scores were extracted from the phase 3 CHAMPION MG (ravulizumab; seven time points) and ADAPT (efgartigimod; nine time points) trials and compared with the preceding score to define health states of improving, stable, or worsening, with extrapolation to 1 year. Stable state was evaluated across threshold ranges of 0.2-1.0-point change between observations. The proportion of time spent across health states was calculated for each stability threshold and then averaged for an overall summary across the range of cut points.</p><p><strong>Results: </strong>When extrapolated to 1 year, patients receiving ravulizumab spent more time with stable symptoms compared with patients on efgartigimod as measured by MG-ADL, QMG, and MG-QOL15r across stability thresholds. On average, patients receiving ravulizumab spent more time in stable or improving health states combined according to MG-ADL, QMG, MG-QOL15r (100%, 91%, and 79% of the year, respectively) compared to worsening states (0%, 9%, 21%). Patients receiving efgartigimod also spent more time, on average, stable or improving (83%, 75%, 77%) than worsening (17%, 25%, 23%). Variation in symptom control was smaller with ravulizumab than with efgartigimod.</p><p><strong>Conclusions: </strong>In this analysis, fixed-dose ravulizumab treatment was associated with stable symptom control in patients with gMG, whereas treatment with variable-dose efgartigimod resulted in initial improvement but more variable symptom control over time. Patients' personal goals and quality-of-life should be considered when choosing a gMG therapy.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"817-827"},"PeriodicalIF":2.4,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143972888","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Authors' response to: sting operations are not necessary in biomedical publishing.","authors":"Jaime A Teixeira da Silva, Jens C Türp, Timothy Daly","doi":"10.1080/03007995.2025.2510407","DOIUrl":"10.1080/03007995.2025.2510407","url":null,"abstract":"","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"897-899"},"PeriodicalIF":2.4,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144126919","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessment of whether use of a professional medical writer is associated with time to publication of papers reporting phase III oncology clinical trials in two high-impact general medicine journals.","authors":"Moamen Hammad, Thomas Carvell-Miller, Bernard Kerr, Valerie Moss","doi":"10.1080/03007995.2025.2505697","DOIUrl":"10.1080/03007995.2025.2505697","url":null,"abstract":"<p><strong>Objective: </strong>Professional medical writers assist authors with ethical and accurate publication of scientific research. We hypothesized that the support of a medical writer would enable timely publication of research and explored their association using papers reporting phase III oncology trials from 2019-2023. Given the time frame of this research, we also assessed the impact of the coronavirus disease 2019 (Covid-19) pandemic on publication volume as a secondary objective.</p><p><strong>Methods: </strong>We searched PubMed for phase III clinical trials published in <i>New England Journal of Medicine</i> (<i>NEJM)</i> and the <i>Lancet</i> between 01/01/2019 and 12/31/2023. Publications reporting oncology trials were reviewed in full to document acknowledgement of medical writing support, data cut-off date, publication date and other key characteristics. Time from data cut-off to publication was compared for papers with and without medical writing support.</p><p><strong>Results: </strong>Our search identified 442 papers reporting any phase III clinical trials, of which 164 (37%) reported oncology trials; 122/164 (74%) disclosed medical writing support. Mean time to publication was significantly shorter for papers disclosing medical writing support than those without (307 vs. 466 days; <i>p</i> < 0.0001). Median time to publication for papers with medical writing support appeared stable from 2019 to 2023. The volume (oncology and non-oncology) of phase III trials published in <i>NEJM</i> and the <i>Lancet</i> between 2019 and 2023 was lowest during 2020 to 2022 (<i>n</i> = 70-88) and highest in 2023 followed by 2019 (<i>n</i> = 110 and <i>n</i> = 96, respectively).</p><p><strong>Conclusions: </strong>Medical writing support is associated with timely publication of clinical trial results, even during events that may disrupt publication development such as the Covid-19 pandemic.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"887-893"},"PeriodicalIF":2.4,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144076529","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient and physician concordance in treatment satisfaction and symptom severity among myasthenia gravis patients in the United States and five European countries.","authors":"Jacqueline Pesa, Zia Choudhry, Jonathan de Courcy, Sophie Barlow, Emma Chatterton, Shiva Lauretta Birija, Gregor Gibson, Bethan Hahn, Raghav Govindarajan","doi":"10.1080/03007995.2025.2516147","DOIUrl":"10.1080/03007995.2025.2516147","url":null,"abstract":"<p><strong>Objective: </strong>Quantification of myasthenia gravis (MG) symptom severity and treatment satisfaction could differ whether reported by patients or physicians. The study objective was to explore concordance between assessments of symptom severity, symptom troublesomeness, and treatment satisfaction by patients with MG and their physicians.</p><p><strong>Methods: </strong>Data were from the Adelphi Real World MG Disease Specific Programme (DSP), a multinational (France, Germany, Italy, Spain, United Kingdom [UK], United States [US]), cross-sectional survey with retrospective chart review independently completed by physicians and their patients in 2020.</p><p><strong>Results: </strong>Across all patients and all symptoms, physician-patient concordance about symptom severity was moderate (Cohen's Weighted Kappa [<i>κ</i>] statistic = 0.45). However, there was high variability, and when the 17 symptoms were examined individually, agreement was slight or fair (<i>κ</i> = 0.00-0.40). The proportion of physicians describing a given symptom as less severe than the patient ranged from 30.9-74.5%. There were many instances where a physician reported a symptom as absent, but the patient self-reported it as present (e.g. fatigue/tiredness: physician-reported absence in 42% of patients [of whom 11% self-reported mild, 17% moderate, 5% severe]. There was generally greater physician-patient concordance in recognizing patients' most troublesome symptoms; agreement was poor (<i>κ</i> < 0) or slight/fair (<i>κ</i> = 0.00-0.40) for 6 symptoms and moderate/substantial (<i>κ</i> = 0.41-0.80) for 11. Physician-patient concordance regarding treatment satisfaction was fair (<i>κ</i> = 0.37), with physicians reporting higher satisfaction than patients in 36.6% of cases.</p><p><strong>Conclusions: </strong>Although some physician-patient concordance was observed, many patients reported greater symptom severity and/or lower treatment satisfaction compared with physicians.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"841-854"},"PeriodicalIF":2.4,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144246805","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}